Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence and clinical skills of health care professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses and other clinicians involved in the care of breast cancer patients.
Upon completion of this activity, participants will be able to:
Welcoming Remarks
Harold Burstein, MD, PhD
Management of the Axilla
Monica Morrow, MD
Reconstruction Options in 2023
Matthew Carty, MD
Lymphatic Surgery
Michelle Coriddi, MD
Q&A
Lecture: The Future of Breast Cancer Pathology
Jorge Reis-Filho, MD, PhD, FRCPath
Q&A
Break
Prophylactic Surgery: Who, What, When?
Barbara Smith, MD, PhD
Genetic Testing: Who, Which Test, When?
Judy Garber, MD, MPH
Managing Hereditary Breast Cancer: What We Do; What We Still Don’t Know
Nadine Tung, MD
Q&A
Lunch
*not provided
Lecture: The Future of Breast Cancer Imaging and Screening
Constance Lehman, MD, PhD
Q&A
Schedules and Regimens
Jennifer Bellon, MD
Postmastectomy Radiation
Rachel Jimenez, MD
Oligometastatic Disease
Steven Chmura, MD, PhD
Radiotherapy Options for Brain Metastases
Ayal Aizer, MD, MHS
Q&A
Break
Lecture: The Future of Breast Cancer: Radiation Oncology
Bruce Haffty, MD, MS
Q&A
Tumor Board: Local Regional Therapy
Tari King, MD, FACS
Novel Agents: SERDS
Rinath Jeselsohn, MD
Novel Agents: AKT Pathways
Alex Toker, PhD
Male Breast Cancer
Jose Pablo Leone, MD
Role of ADCs in ER+ Breast Cancer
Paolo Tarantino, MD
Special Considerations in Premenopausal Women
Erica Mayer, MD, MPH
Break
Adjuvant Endocrine Therapy: How Long?
Heather Parsons, MD, MPH
Adjuvant Therapy: CDK4/6 Inhibitors
Sarah Sammons, MD
Adjuvant Therapy: Chemotherapy
Beverly Moy, MD, MPH
Local Regional Considerations in Older Cancer Patients
Christina Minami, MD
Q&A
Lecture: The Future of Breast Cancer Clinical Trials Designs
Nabihah Tayob, PhD
Q&A
Break
Tumor Board: Advanced Breast Cancer
Moderator: Erica Mayer, MD, MPH
*Lunch Included
Break
Where To With Immunotherapy
Sara Tolaney, MD, MPH
Treating Brain Metasteses
Nancy Lin, MD
Antibody Drug Conjugates
Aditya Bardia, MD, MPH
Lecture:The Future of Immunotherapy in Breast Cancer
Elizabeth Mittendorf, MD, PhD
Q&A
Sara Tolaney, MD, MPH
Nancy Lin, MD
Aditya Bardia, MD, MPH
Elizabeth Mittendorf, MD, PhD
Break
Pregnancy After Breast Cancer
Ann Partridge, MD, MPH
Cannabinoids and Breast Cancer
Ilana Braun, MD
Exercise, Diet and Breast Cancer
Jennifer Ligibel, MD
Q&A
Ann Partridge, MD, MPH
Ilana Braun, MD
Jennifer Ligibel, MD
Schlager Lecture: The Future of Breast Cancer and Genomic Tools and Testing
Fabrice Andre, MD, PhD
Q&A
Tumor Board: Early Stage Breast Cancer
Hal Burstein, MD, PhD
ASCO Highlights
Harold Burstein, MD, PhD
Break
ADCs for HER2 Positive Tumors
Rachel Occhiogrosso Abelman, MD
HER2 Testing
Laura Collins, MD
Treatment for Early-Stage HER2 Positive Breast Cancer
Adrienne Waks, MD
Curing HER2+ Breast Cancer
Steven Isakoff, MD, PhD
Q&A
Closing Remarks
Harold Burstein, MD, PhD
